Overview

A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD

Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this randomized, double-blind, crossover study is to compare two long-acting stimulant formulations-once-daily PRC-063 and once-daily lisdexamfetamine (LDX)-through a 15-hour period on driving performance, as measured with a driving simulator, in adult patients with ADHD.
Phase:
Phase 3
Details
Lead Sponsor:
Rhodes Pharmaceuticals, L.P.
Collaborator:
Purdue Pharma LP
Treatments:
Lisdexamfetamine Dimesylate